Crossmark

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Crossref DOI link: https://doi.org/10.1186/s13045-017-0549-1

Published Online: 2018-01-16

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caers, J. https://orcid.org/0000-0002-3175-1195
Paiva, B.

Zamagni, E.

Leleu, X.

Bladé, J.

Kristinsson, S. Y.

Touzeau, C.

Abildgaard, N.

Terpos, E.

Heusschen, R.

Ocio, E.

Delforge, M.

Sezer, O.

Beksac, M.

Ludwig, H.

Merlini, G.

Moreau, P.

Zweegman, S.

Engelhardt, M.

Rosiñol, L.
Funding

Funding for this research was provided by:

Stichting Tegen Kanker

Fonds De La Recherche Scientifique - FNRS

Deutsche Krebshilfe (1095969, 111424)

Fundación Científica Asociación Española Contra el Cáncer (GCB120981SAN)
More Information

Article History

Received: 26 October 2017

Accepted: 26 December 2017

First Online: 16 January 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: Jo Caers received honoraria from Amgen, Celgene, and Janssen-Cilag and research grants from Celgene. Elena Zamagni received honoraria from Janssen-Cilag, Celgene, BMS, and Amgen. Niels Abdilgaard received research grants from Takeda, Celgene, and Amgen and honoraria from Takeda, Celgene, and Janssen-Cilag. Xavier Leleu received honoraria from Janssen-Cilag, Celgene, Novartis, Sanofi, Amgen, Takeda, Pierre Fabre, Gilead, BMS, and Merck. Laura Rosinol received honoraria from Janssen, Celgene, Amgen, and Takeda. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.